Pharma Mar SA (PHM) AI Stock Analysis

• Market Cap: $1.31B
• Dividend Yield: 1.12%
• Average Volume (3M): 74.16K
• Price to Earnings (P/E): 38.3
• Beta (1Y): 1.10
• Revenue Growth: 7.35%
• EPS Growth: 5375.64%
• Country: ES
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.23
• Shares Outstanding: 18,000,000
• 10 Day Avg. Volume: 71,270
• 30 Day Avg. Volume: 74,161
• PEG Ratio: 0.02
• Price to Book (P/B): 6.72
• Price to Sales (P/S): 8.00
• P/FCF Ratio: -147.59
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 6.98
• Enterprise Value/Gross Profit: 7.35
• Enterprise Value/Ebitda: 27.95
• 1Y Price Target: $120.44
• Price Target Upside: 69.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: €84.00 ▲(18.06% Upside)

Pharma Mar SA's overall stock score is primarily influenced by its strong financial performance, particularly in profitability and balance sheet stability. However, technical analysis indicates bearish momentum, and the high P/E ratio suggests potential overvaluation. The lack of earnings call data and notable corporate events limits further insights.

Pharma Mar SA Business Overview & Revenue Model

Company Description

Pharma Mar SA (PHM) is a biopharmaceutical company based in Spain that specializes in the research, development, and commercialization of marine-derived pharmaceuticals, primarily focusing on oncology and other therapeutic areas. The company is known for its innovative drug development pipeline, particularly its flagship product Aplidin (plitidepsin), which targets multiple myeloma and other hematological malignancies. Pharma Mar operates within the pharmaceutical sector, with a strong emphasis on leveraging marine biodiversity to discover new therapeutic compounds.

How the Company Makes Money

Pharma Mar generates revenue primarily through the sales of its pharmaceutical products, particularly Aplidin and other oncology-related therapies. The company has established a revenue model that includes direct sales to healthcare providers and collaborations with other pharmaceutical companies for the development and commercialization of its drugs. Key revenue streams include royalties from licensing agreements, milestone payments from partners upon achieving specific development or sales targets, and potential product sales in various international markets. Additionally, Pharma Mar has engaged in strategic partnerships with major pharmaceutical companies to enhance its research capabilities and market reach, contributing to its earnings through collaborative development agreements.

Pharma Mar SA Financial Statement Overview

Summary

Pharma Mar SA demonstrates strong profitability with robust gross and net profit margins. The balance sheet is stable with manageable debt levels and strong equity returns. However, cash flow management presents challenges, with declining free cash flow and operating cash flow ratios. The company should focus on enhancing operational efficiencies and cash flow generation to sustain growth.

Income Statement

Pharma Mar SA shows strong gross profit margins consistently above 93%, indicating efficient cost management. The TTM net profit margin improved to 22.20%, reflecting enhanced profitability. Revenue growth is positive at 7.69% TTM, recovering from previous declines. However, EBIT and EBITDA margins, though improving, remain lower than historical highs, suggesting room for operational efficiency improvements.

Balance Sheet

The company maintains a stable debt-to-equity ratio around 0.25, indicating prudent leverage management. Return on equity has improved to 21.28% TTM, showcasing effective use of equity capital. The equity ratio remains healthy, suggesting a strong capital structure. However, the decline in total assets over recent years could be a concern for future growth.

Cash Flow

Operating cash flow is positive but has decreased significantly, impacting the operating cash flow to net income ratio. Free cash flow growth is negative, indicating potential liquidity challenges. The free cash flow to net income ratio is low, suggesting limited cash generation relative to net income. This highlights the need for improved cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	189.27M	174.85M	158.15M	196.34M	229.83M	269.96M
Gross Profit	179.76M	166.67M	148.54M	182.70M	213.39M	256.24M
EBITDA	47.25M	21.23M	4.55M	52.07M	104.08M	155.94M
Net Income	42.01M	26.13M	1.14M	49.36M	92.86M	137.26M
Balance Sheet
Total Assets	348.25M	349.64M	340.52M	393.26M	368.39M	330.26M
Cash, Cash Equivalents and Short-Term Investments	128.08M	154.53M	162.56M	182.42M	201.88M	195.52M
Total Debt	51.40M	51.08M	43.67M	42.63M	49.33M	56.66M
Total Liabilities	146.72M	141.28M	147.08M	170.30M	190.47M	227.54M
Stockholders Equity	201.53M	208.36M	193.44M	222.96M	177.92M	102.72M
Cash Flow
Free Cash Flow	1.28M	-9.48M	-29.40M	29.47M	17.87M	275.94M
Operating Cash Flow	8.80M	6.03M	-13.45M	38.32M	25.68M	278.94M
Investing Cash Flow	5.83M	1.03M	-43.05M	10.88M	18.47M	-119.01M
Financing Cash Flow	-11.87M	-5.35M	-32.14M	-13.37M	-27.41M	-73.82M

Pharma Mar SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:PHM, the sentiment is Negative. The current price of 71.15 is below the 20-day moving average (MA) of 76.08, below the 50-day MA of 83.41, and below the 200-day MA of 83.29, indicating a bearish trend. The MACD of -3.55 indicates Positive momentum. The RSI at 30.12 is Neutral, neither overbought nor oversold. The STOCH value of 17.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:PHM.

Pharma Mar SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	77 Outperform	€1.37B	12.96	14.89%	4.06%	11.04%	8.29%
RJF	65 Neutral	€231.13M	34.85	2.03%	1.71%	-1.19%	-54.66%
ROVI	65 Neutral	€2.98B	22.67	20.70%	1.70%	-9.39%	-25.92%
ALM	61 Neutral	€2.61B	121.80	1.45%	1.33%	13.32%	―
PHM	56 Neutral	$1.31B	38.26	17.22%	1.12%	7.35%	5375.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pharma Mar SA Corporate Events

Pharma Mar SA Reports Revenue Growth and Key Approvals

Pharma Mar SA is a biotechnology company focused on the discovery and development of marine-derived drugs, primarily in the oncology sector, with a unique emphasis on leveraging compounds from the sea for therapeutic purposes.

Pharma Mar SA Reports Strong H1 2025 Performance

Pharma Mar SA is a biopharmaceutical company specializing in the development and commercialization of innovative oncology and RNA interference therapies, with a focus on small cell lung cancer and age-related macular degeneration treatments.